Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

1 hour ago 3

Jonathan Ponciano, The Motley Fool

Sat, May 30, 2026 astatine 1:12 PM CDT 4 min read

FCPM III Services B.V. disclosed a caller presumption successful Damora Therapeutics (NASDAQ:DMRA) arsenic of March 31, 2026, acquiring 2,441,000 shares for an estimated $65.63 cardinal based connected quarterly mean pricing.

What happened

According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, FCPM III Services B.V. initiated a caller presumption successful Damora Therapeutics by purchasing 2,441,000 shares. The estimated worth of this transaction was $65.63 million, calculated utilizing the quarterly mean terms for the play from January 1 to March 31, 2026. The quarter-end presumption worth was $63.22 million.

What other to cognize

This is simply a caller presumption for the money and represents 8.75% of 13F reportable assets nether absorption arsenic of March 31, 2026.
Top holdings aft the filing:
- NASDAQ: NAMS: $294.46 cardinal (41.2% of AUM)
- NASDAQ: DYN: $84.20 cardinal (11.8% of AUM)
- NASDAQ: VOR: $73.45 cardinal (10.3% of AUM)
- NASDAQ: ENGN: $65.60 cardinal (9.2% of AUM)
- NASDAQ: MPLT: $65.59 cardinal (9.2% of AUM)
As of Friday, shares of Damora Therapeutics were priced astatine $24.88, up astir 700% this past year.

Company overview

Metric

Value

Price (as of Friday)	$24.88
Market Capitalization	$1.5 billion
Net Income (TTM)	($235 million)

Company snapshot

Damora Therapeutics develops small-molecule therapeutics targeting crab and fibrotic diseases, with a absorption connected galectin-3 and LOXL2 inhibitors.
The steadfast operates arsenic a clinical-stage biotechnology institution processing caller small-molecule therapeutics.
It serves the biopharmaceutical market, with a absorption connected advancing therapies for patients with unmet needs successful oncology and fibrotic disorders.

Galecto, Inc. is simply a clinical-stage biotechnology institution headquartered successful Boston, MA. The company’s strategy centers connected processing caller therapeutics that code unmet aesculapian needs successful oncology and fibrotic disorders. Galecto’s competitory borderline lies successful its proprietary tiny molecule inhibitors, positioning it arsenic an innovator wrong the pharmaceutical improvement landscape.

What this transaction means for investors

This acquisition yet looks similar a stake connected a freshly recapitalized biotech with a agelong runway and respective meaningful catalysts inactive ahead. FCPM's determination to marque Damora astir 9% of reportable assets suggests condemnation that the company's translation is lone beginning, contempt a banal summation of astir 700% implicit the past year.

The communicative changed a batch successful caller months. Formerly known arsenic Galecto, the institution rebranded arsenic Damora Therapeutics pursuing the acquisition of a portfolio of mutant calreticulin-targeted therapies aimed astatine treating uncommon humor cancers. Management believes its pb candidate, DMR-001, has best-in-class potential, with a regulatory submission expected successful mid-2026 and archetypal objective proof-of-concept information anticipated opening successful mid-2027.

New CEO Jennifer Jarrett earlier this period said the institution is "well positioned" to support oregon perchance shorten the timeline to marketplace comparative to competitors. Damora has besides revamped its enactment squad with executives from Blueprint Medicines, Arcus Biosciences, and Medivation.

Most importantly, the equilibrium expanse gives absorption country to execute. Damora ended the archetypal 4th with $532.9 cardinal successful currency and expects that superior to money operations into 2029. While first-quarter nett nonaccomplishment widened to $27.8 cardinal arsenic probe spending accelerated, investors are intelligibly focused connected aboriginal objective milestones alternatively than existent earnings.

Read Entire Article